HomeInsightsStock Comparison

Astonea Labs Ltd vs Astrazeneca Pharma India Ltd Stock Comparison

Astonea Labs Ltd vs Astrazeneca Pharma India Ltd Stock Comparison

Last Updated on: Jul 10, 2025

Key Highlights

  • The P/E Ratio of Astonea Labs Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Astrazeneca Pharma India Ltd changed from 82.8 on March 2020 to 82.4 on March 2024 . This represents a CAGR of -0.10% over 5 years.
  • The Market Cap of Astonea Labs Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 5978 crore on March 2020 to ₹ 13301 crore on March 2024 . This represents a CAGR of 17.34% over 5 years.
  • The revenue of Astonea Labs Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 496.63 crore as compare to the Dec '24 revenue of ₹ 448.27 crore. This represent the growth of 10.79%.
  • The ebitda of Astonea Labs Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 96.84 crore as compare to the Dec '24 ebitda of ₹ 51.42 crore. This represent the growth of 88.33%.
  • The net profit of Astonea Labs Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 53.86 crore to ₹ 58.25 crore over 8 quarters. This represents a CAGR of 4.00% .
  • The Dividend Payout of Astonea Labs Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Astrazeneca Pharma India Ltd changed from 3.46 % on March 2020 to 37.15 % on March 2024 . This represents a CAGR of 60.76% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Astonea Labs Ltd

  • Astonea Labs Ltd was originally incorporated as 'AHU Laboratories Private Limited', as a private limited company, pursuant to certificate of incorporation dated April 11, 2017.
  • Company changed its name from AHU Laboratories Limited to 'Astonea Labs Private Limited' dated February 26, 2019.
  • Subsequently, the Company converted into 'Astonea Labs Limited', vide fresh Certificate of Incorporation dated January 11, 2024. Company specializes in the manufacturing and marketing of a wide range of pharmaceutical and cosmetic products.
  • These include antibiotic drugs, anticold medications, antihistamines, and drugs for diabetes, cardiovascular diseases, gynecological concerns, analgesics, fungal infections, and multivitamins.
  • These are used for skin, tooth, and hair care, available in various forms such as gels, ointments, creams, lotions, oils, and serums.

About Astrazeneca Pharma India Ltd

  • AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
  • The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
  • The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
  • Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

Astonea Labs Ltd News Hub

News

Astonea Labs announces board meeting date

Astonea Labs will hold a meeting of the Board of Directors of the Company on 11 July 2025....

Read more

05 Jul 2025 11:04

News

BSE SME Astonea Labs inches higher on debut

The scrip was listed at Rs 137.45, a premium of 1.81% compared with the initial public off...

Read more

03 Jun 2025 11:01

Astrazeneca Pharma India Ltd News Hub

News

AstraZeneca Pharma gets CDSCO approval to import Durvalumab Solution

Through this approval, Durvalumab in combination with carboplatin and paclitaxel is indica...

Read more

02 Jul 2025 10:26

News

Astrazeneca Pharma India Ltd leads losers in 'A' group

Orient Cement Ltd, India Cements Ltd, Concord Biotech Ltd and ERIS Lifesciences Ltd are am...

Read more

20 Jun 2025 15:00

News

AstraZeneca Pharma slides as MD Sanjeev Panchal steps down; Praveen Rao Akkinepally to take charge

Panchal is set to transition to a global role within the AstraZeneca Group, based in Gaith...

Read more

10 Jun 2025 09:49

News

Astrazeneca Pharma India Ltd Spurts 7.28%

Astrazeneca Pharma India Ltd gained 7.28% today to trade at Rs 8545.4. The BSE Healthcare ...

Read more

02 Jun 2025 09:30

News

AstraZeneca Pharma soars after Q4 PAT jumps 48% YoY

Profit before tax (PBT) stood at Rs 78.47 crore in Q4 FY25, up 44.35% year-on-year, and up...

Read more

02 Jun 2025 10:10

News

Volumes soar at Astrazeneca Pharma India Ltd counter

Max Healthcare Institute Ltd, Godrej Consumer Products Ltd, Mphasis Ltd, Indraprastha Gas ...

Read more

02 Jun 2025 11:00

BlinkX Score for Astrazeneca Pharma India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Astonea Labs Ltd and Astrazeneca Pharma India Ltd

Which company has a larger market capitalization, Astonea Labs Ltd or Astrazeneca Pharma India Ltd?

Market cap of Astonea Labs Ltd is 153 Cr while Market cap of Astrazeneca Pharma India Ltd is 23,240 Cr

What are the key factors driving the stock performance of Astonea Labs Ltd and Astrazeneca Pharma India Ltd?

The stock performance of Astonea Labs Ltd and Astrazeneca Pharma India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astonea Labs Ltd and Astrazeneca Pharma India Ltd?

As of July 10, 2025, the Astonea Labs Ltd stock price is INR ₹146.05. On the other hand, Astrazeneca Pharma India Ltd stock price is INR ₹9296.0.

How do dividend payouts of Astonea Labs Ltd and Astrazeneca Pharma India Ltd compare?

To compare the dividend payouts of Astonea Labs Ltd and Astrazeneca Pharma India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions